Author

Tadakazu Hisamatsu 1

1 Kyorin University School of Medicine, Tokyo, Japan

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

A STUDY ON PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) BASED ON A SURVEY

Shuhei Okuyama, Naohiro Kawamura, Tadakazu Hisamatsu

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Ramesh P. Arasaradnam, Ellen J. Scherl, David Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Waqqas Afif, Tadakazu Hisamatsu, Rupert W Leong, Bruce E. Sands, Maria T. Abreu, Colleen W. Marano

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William J. Sandborn, Tadakazu Hisamatsu, Kathleen Weisel, Susana Gonzalez, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Brian Feagan, Aniita Afzali, Walter Reinisch, Jane Andrews, Omoniyi J. Adedokun, Chenglong Han

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

Simon Travis, Toshifumi Hibi, Tadakazu Hisamatsu, Deborah Fisher, Mingyang Shan, Theresa Hunter Gibble, David T. Rubin

EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante, Xiaomei Liao, Yinuo Pang, Valerie Pivorunas, Tadakazu Hisamatsu

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension

Bruce E. Sands, William Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Yiying Zhou, Ilia Tikhonov, Laurent Peyrin-Biroulet, Gert Van Assche, Silvio Danese, Stephan Targan, Maria T. Abreu, Tadakazu Hisamatsu, Ellen Scherl, Rupert W Leong, David Rowbotham, Ramesh P. Arasaradnam, Colleen W.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Waqqas Afif, Maria T. Abreu, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Tadakazu Hisamatsu, Ellen J. Scherl, Rupert W Leong, David Rowbotham, Ramesh P. Arasaradnam, Laurent Peyrin-Biroulet, Bruce E. Sands, Colleen W. Marano

Item 1 - 10 / 26
1
2 3